Rexin-G

AXP000210.1 · Viral vector gene therapy

Platform
pathotropic retroviral vector (MoMLV-based, collagen-targeted envelope)
Targets
CCNG1
Originator
Epeius Biotechnologies (Erlinda M. Gordon, Frederick L. Hall)
Sponsor
Delta Next-Gen / Aveni Foundation

Names

NameTypeSource
Rexin-Gpreferred name, codecurator, ncit
Mx-dnG1codencit
DeltaRex-Gsynonymncit
Retrovector Encoding Mutant Anti-Cyclin G1synonymncit

Virus

Role
In vivo gene transfer
Family
Retroviridae
Virus
murine leukemia virus (NCBI Taxonomy 11786)
Strain
MoMLV-based pathotropic vector
Replication
non replicating
Modifications
replication-incompetent MoMLV vector; von Willebrand factor-derived collagen-binding sequence inserted in the envelope protein for targeting to exposed collagen in tumour stroma
Transgenes
CCNG1 (N-terminal-deletion dominant-negative cyclin G1)
Route
intravenous, intra arterial
Source
evidence

Cross-references

NCI Thesaurus
C49082

Approvals

AgencyRegionDateStatusBrandIndicationSource
otherPH2007conditionalRexin-GAccelerated approval for the treatment of all solid tumourssource

Clinical trials (6)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT04378244CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19WithdrawnPhase 1/22022-12-122023-12-120Acute Respiratory Distress Syndrome; COVID-19; Cytokine Storm
NCT00572130Phase II Study of Intravenous Rexin-G in OsteosarcomaCompletedPhase 22007-122010-0722Osteosarcoma
NCT00505713Safety and Efficacy Study Using Rexin-G for SarcomaCompletedPhase 1/22007-072010-0736Sarcoma
NCT00505271Safety and Efficacy Study Using Rexin-G for Breast CancerCompletedPhase 1/22007-072010-0720Breast Cancer
NCT00504998Safety/Efficacy Study of Rexin-G to Treat Pancreatic CancerCompletedPhase 1/22007-072010-0720Pancreatic Cancer
NCT00121745Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic CancerTerminatedPhase 12005-0712Pancreatic Cancer
Unconfirmed matches (1)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT00035919Safety and Efficacy of Targeted Gene Transfer in Colorectal Cancer Metastatic to LiverWithdrawnPhase 1/22002-110Colorectal Neoplasmsname in intervention: Mx-dnG1

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 19826403Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer.Molecular therapy : the journal of the American Society of Gene Therapy2010name in title: Rexin-G
PMID 20428757Noteworthy clinical case studies in cancer gene therapy: tumor-targeted Rexin-G advances as an efficacious anti-cancer agent.International journal of oncology2010name in title: Rexin-G
PMID 20811660Pathotropic targeting advances clinical oncology: tumor-targeted localization of therapeutic gene delivery.Oncology reports2010name in abstract: Rexin-G
PMID 19532136Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma.Molecular therapy : the journal of the American Society of Gene Therapy2009name in title: Rexin-G
PMID 18388964Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer.Molecular therapy : the journal of the American Society of Gene Therapy2008name in title: Rexin-G
PMID 17487349Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes.International journal of oncology2007name in abstract: Rexin-G
PMID 14654955First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer.International journal of oncology2004name in title: Rexin-G

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 40227707Gene and Cell Therapy for Sarcomas: A Review.Cancers2025name in abstract: Rexin-G
PMID 38925853Proceedings of the Think Tank for Osteosarcoma Medical Advisory Board.Anticancer research2024name in abstract: DeltaRex-G
PMID 39359418DeltaRex-G, tumor targeted retrovector encoding a CCNG1 inhibitor, for CAR-T cell therapy induced cytokine release syndrome.Frontiers in molecular medicine2024name in title: DeltaRex-G
PMID 37065938Oncolytic virus-based suicide gene therapy for cancer treatment: a perspective of the clinical trials conducted at Henry Ford Health.Translational medicine communications2023name in abstract: Rexin-G
PMID 37247916Early-stage CCNG1+ HR+ HER2+ Invasive Breast Carcinoma in Older Women: Current Treatment and Future Perspectives for DeltaRex-G, a CCNG1 Inhibitor.Anticancer research2023name in title: DeltaRex-G
PMID 39086675Phase I-II study using DeltaRex-G, a tumor-targeted retrovector encoding a cyclin G1 inhibitor for metastatic carcinoma of breast.Frontiers in molecular medicine2023name in title: DeltaRex-G
PMID 39086973Three year results of Blessed: Expanded access for DeltaRex-G for an intermediate size population with advanced pancreatic cancer and sarcoma (NCT04091295) and individual patient use of DeltaRex-G for solid malignancies (IND# 19130).Frontiers in molecular medicine2022name in title: DeltaRex-G
PMID 34277005Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with DeltaRex-G: A case report and literature review.Molecular and clinical oncology2021name in title: DeltaRex-G
PMID 30705966A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer.Molecular therapy oncolytics2019name in title: Rexin-G
PMID 28588778Rexin-G®, a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report.Molecular and clinical oncology2017name in title: Rexin-G
PMID 21519259Phase 1 clinical trials for sarcomas: the cutting edge.Current opinion in oncology2011name in abstract: Rexin-G
PMID 20384524Rexin-G, a targeted genetic medicine for cancer.Expert opinion on biological therapy2010name in title: Rexin-G
PMID 20664824Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2010name in abstract: Mx-dnG1
PMID 19578735The 'timely' development of Rexin-G: first targeted injectable gene vector (review).International journal of oncology2009name in title: Rexin-G
PMID 19798455Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2009name in abstract: Mx-dnG1
PMID 18813779Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ.International journal of oncology2008name in abstract: Rexin-G
PMID 17016635Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: three-year clinical experience.International journal of oncology2006name in title: Rexin-G
PMID 15844625Technology evaluation: Rexin-G, Epeius Biotechnologies.Current opinion in molecular therapeutics2005name in title: Rexin-G
PMID 15870914Nanotechnology blooms, at last (Review).Oncology reports2005name in abstract: Rexin-G
PMID 11177556Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice.Human gene therapy2001name in abstract: Mx-dnG1

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R01FD003071Phase I Clinical Trial Using Rexin-G for Pancreatic Can*EPEIUS BIOTECHNOLOGIES CORPORATIONHALL, FREDERICK L2006–2007name in title: Rexin-G

Notes

Replication-incompetent MoMLV-based vector whose envelope carries a von Willebrand factor-derived collagen-binding peptide, delivering a cytocidal N-terminal-deletion (dominant-negative) human cyclin G1 construct; given by intravenous infusion. Renamed DeltaRex-G. Reported as approved for all solid tumours in the Philippines (accelerated approval, 2007); the approval year comes from secondary sources, not an agency record. Not an oncolytic virus: the vector does not replicate.

How to cite

Rexin-G (AXP000210.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000210.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.